Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
P/E ratio for Sanofi India Limited (SANOFI.NS)
P/E ratio as of 2023: 15.52
According to Sanofi India Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 15.52. At the end of 2022 the company had a P/E ratio of 10.86.
P/E ratio history for Sanofi India Limited from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 15.52 |
| 2022 | 10.86 |
| 2021 | 9.62 |
| 2020 | 20.08 |
| 2019 | 19.48 |
| 2018 | 19.27 |
| 2017 | 16.60 |
| 2016 | 16.67 |
| 2015 | 15.68 |
| 2014 | 15.70 |
| 2013 | 11.90 |
| 2012 | 14.99 |
| 2011 | 14.06 |
| 2010 | 14.43 |
| 2009 | 12.43 |
| 2008 | 6.70 |
| 2007 | 9.28 |
| 2006 | 9.54 |
| 2005 | 12.51 |
| 2004 | 12.22 |